Why Isis Pharmaceuticals Shares Skyrocketed

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Isis Pharmaceuticals (NASDAQ: IONS  ) , a developer of antisense drugs, advanced as much as 24% after the company reported positive mid-stage data for ISIS-APOCIII Rx, its triglyceride-fighting drug for those with high-triglyceride levels and type 2 diabetes.

So what: Although the pool for this mid-stage trial was merely 11 patients, the results of APOCIII Rx were phenomenal. In the study, triglyceride levels fell by a whopping 72% while high-density lipoproteins (the good type of cholesterol) rose by 40%. According to Isis' press release, there were "improvements in other atherogenic lipid parameters" as well. The study also noted that APOCIII Rx led to increased insulin sensitivity, which improved patients' glycemic balance.

Now what: I know it's a bit early to start calling this drug a success, but it's hard not to get excited when the results are far and away better than any other triglyceride-reducing agent on the market. Isis is a unique biotechnology company in that the majority of its pipeline is based on partnerships. In fact, the company currently has 23 ongoing clinical trials (not counting preclinical trials) across a myriad of ailments, and 12 different development partners. Isis may not have a huge revenue stream at the moment, but it's well-positioned for success. Consider today's positive study just another reason to consider digging deeper into Isis.

Craving more input? Start by adding Isis Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

It's no secret that biotech stocks like Isis have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long-term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 24, 2013, at 1:58 PM, biz2befree wrote:

    FYI - This is one of the drugs where they do not yet have a partner. It is why they had their secondary offering a few weeks ago, so that they would have the funds to wait longer to partner promising drugs and receive more value for them once they do partner.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2506130, ~/Articles/ArticleHandler.aspx, 9/29/2016 4:43:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
IONS $36.20 Down -0.52 -1.42%
Ionis Pharmaceutic… CAPS Rating: *****